NCT03138356 - Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects | Biotech Hunter

Enrollment

126

Participants

Timeline

Start Date

May 25, 2017

Primary Completion Date

November 28, 2017

Study Completion Date

November 28, 2017

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

2.5 mg saxagliptin / 5 mg dapagliflozin / 850 mg metformin XR FDC tablet

Used in Treatment B and Treatment E.

DRUG

2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR FDC tablet

Used in Treatment A and Treatment D.

DRUG

5 mg dapagliflozin / 850 mg metformin XR FDC

Used in Treatment H.

DRUG

5 mg dapagliflozin / 1000 mg metformin XR FDC

Used in Treatment G.

DRUG

2.5 mg ONGLYZA® (saxagliptin) tablet

Used in treatments C and F.

DRUG

5 mg Forxiga® (dapagliflozin) tablet

Used in treatments C, F and I.

DRUG

500 mg Glucophage XR®

Used in treatments C, F and I.

Trial Locations (1)

Research Site, Harrow